XML 38 R25.htm IDEA: XBRL DOCUMENT
v3.19.1

Concentrations | 12 Months Ended
--- | ---
Dec. 31, 2018
Risks and Uncertainties [Abstract] |
CONCENTRATIONS |
20. | CONCENTRATIONS
Major Customers For the year ended December 31, 2018, two customers each accounted for approximately 16% and 13%, respectively, of the Company's revenues from continuing operations. For the year ended December 31, 2017, two customers each accounted for approximately 44% and 12%, respectively, of the Company's revenues from continuing operations. For the year ended December 31, 2016, one customer accounted for approximately 92% of the Company's revenues from continuing operations. For the year ended December 31, 2016, one customer accounted for approximately 92% of the Company's revenues from discontinued operations. No other customer accounted for more than 10% of the Company's revenues for the years ended December 31, 2016, 2017 and 2018. Major Suppliers For the year ended December 31, 2018, two suppliers each accounted for approximately 31% and 17%, respectively, of the Company's purchases from continuing operations. For the year ended December 31, 2017, two suppliers each accounted for approximately 40% and 23%, respectively, of the Company's purchases from continuing operations. For the year ended December 31, 2016, one supplier each accounted for 95% of the Company's purchases from continuing operations. For the year ended December 31, 2016, one supplier accounted for 94% of the Company's purchases from discontinued operations. No other suppliers accounted for more than 10% of the Company's purchases for the years ended December 31, 2016, 2017 and 2018. Revenues by categories The following represents the revenues by categories, all derived from China:
|  | For the years ended December 31, |
|  | 2018 |  |  | 2017 |  |  | 2016 |
Categories |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |
Medical Devices |  | $ | 221,414 |  |  | $ | 827,032 |  |  | $ | 1,305,372 |
Respiratory and Oxygen Homecare |  |  | - |  |  |  | - |  |  |  | 5,956 |
Mobile Medicine (sleep apnea diagnostic products) |  |  | 120,930 |  |  |  | 54,979 |  |  |  | 12,080,164 |
OSAS service (analysis and detection) |  |  | 217,042 |  |  |  | - |  |  |  | - |
Total Revenues |  |  | 559,386 |  |  |  | 882,011 |  |  |  | 13,391,492 |
Less: revenues from discontinued operations |  |  | - |  |  |  | - |  |  |  | (329,119 | )
Revenues from continuing operations |  | $ | 559,386 |  |  | $ | 882,011 |  |  | $ | 13,062,373 |

X
- Definition The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -URI http://asc.fasb.org/topic&trid=2134479 + Details
Name: | us-gaap_ConcentrationRiskDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RisksAndUncertaintiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration